Early Fluid Resolution Predicts Faricimab Durability

Post hoc analysis suggests rapid retinal fluid resolution may help identify patients with nAMD who can maintain longer faricimab dosing intervals.

1

Early resolution of retinal fluid predicts longer treatment intervals for patients with neovascular age-related macular degeneration receiving faricimab.
2

The analysis focused on participants from the TENAYA and LUCERNE trials, examining fluid resolution during the first 12 weeks of faricimab therapy.
3

Patients achieving early fluid resolution had nearly double the likelihood of receiving extended dosing intervals compared to those without resolution.
4

Visual outcomes were comparable or slightly better in patients with early fluid resolution, suggesting potential benefits of rapid anatomical response.
5

Identifying early predictors of treatment durability may help tailor strategies and reduce the injection burden for patients with neovascular AMD.

1